ERBB2 and breast cancer: In HER2+ BC with brain metastases (BCBM) patients, the mOS varies between 30 and 38 mo, contingent upon whether CNS metastases are present at initial diagnosis or arise subsequently [102]; while for HR+ BCBM, mOS was 12.5 months [103].